Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02584933
Title Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUS

Facility Status City State Zip Country Details
Highlands Oncology Group . ACTIVE_NOT_RECRUITING Fayetteville Arkansas 72703 United States Details
Loma Linda University . COMPLETED Loma Linda California 92354 United States Details
University of Colorado Cancer Center COMPLETED Aurora Colorado 80045 United States Details
Maryland Oncology Hematology P A Dept. of Assoc. Onc/Hem COMPLETED Rockville Maryland 20850 United States Details
Essex Oncology of North Jersey PA COMPLETED Belleville New Jersey 07109 United States Details
Novartis Investigative Site COMPLETED Melbourne Victoria 3000 Australia Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Auckland 1023 Australia Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Leuven 3000 Belgium Details
Novartis Investigative Site RECRUITING Porto Alegre Rio Grande Do Sul 90610-000 Brazil Details
Novartis Investigative Site RECRUITING Natal RN 59075 740 Brazil Details
Novartis Investigative Site RECRUITING Barretos Sao Paulo 14784 400 Brazil Details
Novartis Investigative Site RECRUITING Sao Paulo SP 01246 000 Brazil Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Sofia 1303 Bulgaria Details
Novartis Investigative Site RECRUITING Guangzhou Guangdong 51000 China Details
Novartis Investigative Site RECRUITING Guangzhou Guangdong 510120 China Details
Novartis Investigative Site COMPLETED Changchun Jilin 130012 China Details
Novartis Investigative Site COMPLETED Beijing 100039 China Details
Novartis Investigative Site COMPLETED Guangzhou 510060 China Details
Novartis Investigative Site COMPLETED Monteria 230004 Colombia Details
Novartis Investigative Site COMPLETED Brno Czech Republic 656 53 Czechia Details
Novartis Investigative Site COMPLETED Paris 75231 France Details
Novartis Investigative Site COMPLETED Paris 75970 France Details
Novartis Investigative Site COMPLETED Saint-Herblain Cédex 44805 France Details
Novartis Investigative Site RECRUITING Strasbourg Cedex 67091 France Details
Novartis Investigative Site COMPLETED Villejuif 94800 France Details
Novartis Investigative Site COMPLETED Regensburg Bavaria 93053 Germany Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Essen 45147 Germany Details
Novartis Investigative Site COMPLETED Heidelberg 69120 Germany Details
Novartis Investigative Site COMPLETED Koeln 50937 Germany Details
Novartis Investigative Site COMPLETED Wuerzburg 97074 Germany Details
Novartis Investigative Site COMPLETED Hong Kong Hong Kong Details
Novartis Investigative Site COMPLETED Shatin New Territories Hong Kong Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Bergamo BG 24127 Italy Details
Novartis Investigative Site COMPLETED Bologna BO 40138 Italy Details
Novartis Investigative Site COMPLETED Brescia BS 25123 Italy Details
Novartis Investigative Site COMPLETED Meldola FC 47014 Italy Details
Novartis Investigative Site COMPLETED Monza MB 20900 Italy Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Milano MI 20133 Italy Details
Novartis Investigative Site COMPLETED Milano MI 20141 Italy Details
Novartis Investigative Site COMPLETED Milano MI 20162 Italy Details
Novartis Investigative Site COMPLETED Rozzano MI 20089 Italy Details
Novartis Investigative Site COMPLETED Modena MO 41124 Italy Details
Novartis Investigative Site COMPLETED Perugia PG 06129 Italy Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Aviano PN 33081 Italy Details
Novartis Investigative Site COMPLETED Napoli 80131 Italy Details
Novartis Investigative Site COMPLETED Novara 28100 Italy Details
Novartis Investigative Site COMPLETED Nagoya Aichi 464 8681 Japan Details
Novartis Investigative Site WITHDRAWN Kashiwa Chiba 277 8577 Japan Details
Novartis Investigative Site COMPLETED Fukuoka-city Fukuoka 811-1395 Japan Details
Novartis Investigative Site COMPLETED Akashi Hyogo 673-8558 Japan Details
Novartis Investigative Site COMPLETED Koto ku Tokyo 135 8550 Japan Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Seoul 03080 Korea, Republic of Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Seoul 03722 Korea, Republic of Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Seoul 05505 Korea, Republic of Details
Novartis Investigative Site COMPLETED Ashrafieh 166830 Lebanon Details
Novartis Investigative Site COMPLETED Kuching Sarawak 93586 Malaysia Details
Novartis Investigative Site COMPLETED Pulau Pinang 10990 Malaysia Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Gdansk 80 952 Poland Details
Novartis Investigative Site COMPLETED Moscow 115478 Russian Federation Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Saint Petersburg 192148 Russian Federation Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING St Petersburg 197343 Russian Federation Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Singapore 168583 Singapore Details
Novartis Investigative Site COMPLETED Malaga Andalucia 29010 Spain Details
Novartis Investigative Site COMPLETED Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site COMPLETED La Coruna Galicia 15006 Spain Details
Novartis Investigative Site COMPLETED Madrid 28046 Spain Details
Novartis Investigative Site COMPLETED Madrid 28050 Spain Details
Novartis Investigative Site COMPLETED Taichung 40447 Taiwan Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Taichung 40705 Taiwan Details
Novartis Investigative Site COMPLETED Taipei 10002 Taiwan Details
Novartis Investigative Site COMPLETED Taipei 110 Taiwan Details
Novartis Investigative Site COMPLETED Taipei 11217 Taiwan Details
Novartis Investigative Site COMPLETED Taoyuan 33305 Taiwan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field